株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

コンパニオン診断の世界市場:将来予測

Global Companion Diagnostics Market (2019-2025)

発行 KBV Research 商品コード 911058
出版日 ページ情報 英文 237 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.62円で換算しております。
Back to Top
コンパニオン診断の世界市場:将来予測 Global Companion Diagnostics Market (2019-2025)
出版日: 2019年08月31日 ページ情報: 英文 237 Pages
概要

当レポートでは、世界のコンパニオン診断の市場について分析し、製品の概要や市場の主な傾向、市場規模の動向見通し (今後7年間分)、技術別・適応症別および地域別の詳細動向、主な市場促進・抑制要因、市場競争環境、主要企業のプロファイルや戦略展開状況などについて調査しております。

第1章 市場範囲と分析手法

第2章 市場概要

  • イントロダクション
  • 市場を左右する主な要因
    • 市場促進要因
    • 市場抑制要因

第3章 世界のコンパニオン診断市場:技術別

  • 免疫組織化学
  • ポリメラーゼ連鎖反応 (PCR)
  • 次世代シーケンシング (NGS) 市場の予測:地域別
  • In Situハイブリダイゼーション
  • その他

第4章 世界のコンパニオン診断市場:適応症別

  • 腫瘍
  • がんの種類別
    • 乳がん
    • 直腸がん
    • 肺がん
    • 血液がん
    • その他
  • 神経症
  • その他

第5章 世界のコンパニオン診断市場:地域別

  • 北米市場 (米国、カナダ、メキシコなど)
    • 技術別
    • 適応症別
    • がんの種類別
    • 国別分析
  • 欧州市場 (ドイツ、英国、フランス、ロシア、スペイン、イタリアなど)
  • アジア太平洋地域市場 (中国、日本、インド、オーストラリア、韓国、シンガポールなど)
  • ラテンアメリカ・中東・アフリカ市場 (LAMEA:ブラジル、アルゼンチン、UAE、サウジアラビア、南アフリカ、ナイジェリアなど)

第6章 企業プロファイル

  • Agilent Technologies, Inc.
  • Almac Group
  • ARUP Laboratories, Inc.
  • Abbott Laboratories (Abbott Laboratories Molecular, Inc.)
  • Danaher Corporation
  • Thermo Fischer Scientific, Inc.
  • Hologic, Inc.
  • Novartis AG
  • Illumina, Inc.
  • Qiagen N.V.
図表

LIST OF TABLES

  • TABLE 1: GLOBAL COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 2: GLOBAL COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 3: GLOBAL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 4: GLOBAL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 5: GLOBAL IMMUNOHISTOCHEMISTRY MARKET BY REGION, 2015 - 2018, USD MILLION
  • TABLE 6: GLOBAL IMMUNOHISTOCHEMISTRY MARKET BY REGION, 2019 - 2025, USD MILLION
  • TABLE 7: GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET BY REGION, 2015 - 2018, USD MILLION
  • TABLE 8: GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET BY REGION, 2019 - 2025, USD MILLION
  • TABLE 9: GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET BY REGION, 2015 - 2018, USD MILLION
  • TABLE 10: GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET BY REGION, 2019 - 2025, USD MILLION
  • TABLE 11: GLOBAL IN SITU HYBRIDIZATION MARKET BY REGION, 2015 - 2018, USD MILLION
  • TABLE 12: GLOBAL IN SITU HYBRIDIZATION MARKET BY REGION, 2019 - 2025, USD MILLION
  • TABLE 13: GLOBAL OTHER TECHNOLOGY MARKET BY REGION, 2015 - 2018, USD MILLION
  • TABLE 14: GLOBAL OTHER TECHNOLOGY MARKET BY REGION, 2019 - 2025, USD MILLION
  • TABLE 15: GLOBAL COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 16: GLOBAL COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 17: GLOBAL ONCOLOGY COMPANION DIAGNOSTICS MARKET BY REGION, 2015 - 2018, USD MILLION
  • TABLE 18: GLOBAL ONCOLOGY COMPANION DIAGNOSTICS MARKET BY REGION, 2019 - 2025, USD MILLION
  • TABLE 19: GLOBAL COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 20: GLOBAL COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 21: GLOBAL BREAST CANCER COMPANION DIAGNOSTICS BY REGION, 2015 - 2018, USD MILLION
  • TABLE 22: GLOBAL BREAST CANCER COMPANION DIAGNOSTICS BY REGION, 2019 - 2025, USD MILLION
  • TABLE 23: GLOBAL COLORECTAL CANCER COMPANION DIAGNOSTICS BY REGION, 2015 - 2018, USD MILLION
  • TABLE 24: GLOBAL COLORECTAL CANCER COMPANION DIAGNOSTICS BY REGION, 2019 - 2025, USD MILLION
  • TABLE 25: GLOBAL LUNG CANCER COMPANION DIAGNOSTICS BY REGION, 2015 - 2018, USD MILLION
  • TABLE 26: GLOBAL LUNG CANCER COMPANION DIAGNOSTICS BY REGION, 2019 - 2025, USD MILLION
  • TABLE 27: GLOBAL BLOOD CANCER COMPANION DIAGNOSTICS BY REGION, 2015 - 2018, USD MILLION
  • TABLE 28: GLOBAL BLOOD CANCER COMPANION DIAGNOSTICS BY REGION, 2019 - 2025, USD MILLION
  • TABLE 29: GLOBAL OTHER CANCER TYPE COMPANION DIAGNOSTICS MARKET BY REGION, 2015 - 2018, USD MILLION
  • TABLE 30: GLOBAL OTHER CANCER TYPE COMPANION DIAGNOSTICS MARKET BY REGION, 2019 - 2025, USD MILLION
  • TABLE 31: GLOBAL NEUROLOGY COMPANION DIAGNOSTICS MARKET BY REGION, 2015 - 2018, USD MILLION
  • TABLE 32: GLOBAL NEUROLOGY COMPANION DIAGNOSTICS MARKET BY REGION, 2019 - 2025, USD MILLION
  • TABLE 33: GLOBAL OTHER INDICATIONS COMPANION DIAGNOSTICS MARKET BY REGION, 2015 - 2018, USD MILLION
  • TABLE 34: GLOBAL OTHER INDICATIONS COMPANION DIAGNOSTICS MARKET BY REGION, 2019 - 2025, USD MILLION
  • TABLE 35: GLOBAL COMPANION DIAGNOSTICS MARKET BY REGION, 2015 - 2018, USD MILLION
  • TABLE 36: GLOBAL COMPANION DIAGNOSTICS MARKET BY REGION, 2019 - 2025, USD MILLION
  • TABLE 37: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 38: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 39: NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 40: NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 41: NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 42: NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 43: NORTH AMERICA POLYMERASE CHAIN REACTION (PCR) MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 44: NORTH AMERICA POLYMERASE CHAIN REACTION (PCR) MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 45: NORTH AMERICA NEXT GENERATION SEQUENCING (NGS) MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 46: NORTH AMERICA NEXT GENERATION SEQUENCING (NGS) MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 47: NORTH AMERICA IN SITU HYBRIDIZATION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 48: NORTH AMERICA IN SITU HYBRIDIZATION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 49: NORTH AMERICA OTHER TECHNOLOGY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 50: NORTH AMERICA OTHER TECHNOLOGY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 51: NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 52: NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 53: NORTH AMERICA ONCOLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 54: NORTH AMERICA ONCOLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 55: NORTH AMERICA NEUROLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 56: NORTH AMERICA NEUROLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 57: NORTH AMERICA OTHER INDICATIONS COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 58: NORTH AMERICA OTHER INDICATIONS COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 59: NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 60: NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 61: NORTH AMERICA BREAST CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 62: NORTH AMERICA BREAST CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 63: NORTH AMERICA COLORECTAL CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 64: NORTH AMERICA COLORECTAL CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 65: NORTH AMERICA LUNG CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 66: NORTH AMERICA LUNG CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 67: NORTH AMERICA BLOOD CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 68: NORTH AMERICA BLOOD CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 69: NORTH AMERICA OTHER CANCER TYPE COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 70: NORTH AMERICA OTHER CANCER TYPE COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 71: NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 72: NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 73: USA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 74: USA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 75: USA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 76: USA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 77: USA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 78: USA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 79: USA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 80: USA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 81: CANADA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 82: CANADA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 83: CANADA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 84: CANADA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 85: CANADA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 86: CANADA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 87: CANADA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 88: CANADA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 89: MEXICO COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 90: MEXICO COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 91: MEXICO COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 92: MEXICO COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 93: MEXICO COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 94: MEXICO COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 95: MEXICO COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 96: MEXICO COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 97: REST OF NORTH AMERICA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 98: REST OF NORTH AMERICA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 99: REST OF NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 100: REST OF NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 101: REST OF NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 102: REST OF NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 103: REST OF NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 104: REST OF NORTH AMERICA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 105: EUROPE COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 106: EUROPE COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 107: EUROPE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 108: EUROPE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 109: EUROPE IMMUNOHISTOCHEMISTRY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 110: EUROPE IMMUNOHISTOCHEMISTRY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 111: EUROPE POLYMERASE CHAIN REACTION (PCR) MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 112: EUROPE POLYMERASE CHAIN REACTION (PCR) MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 113: EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 114: EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 115: EUROPE IN SITU HYBRIDIZATION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 116: EUROPE IN SITU HYBRIDIZATION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 117: EUROPE OTHER TECHNOLOGY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 118: EUROPE OTHER TECHNOLOGY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 119: EUROPE COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 120: EUROPE COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 121: EUROPE ONCOLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 122: EUROPE ONCOLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 123: EUROPE NEUROLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 124: EUROPE NEUROLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 125: EUROPE OTHER INDICATIONS COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 126: EUROPE OTHER INDICATIONS COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 127: EUROPE COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 128: EUROPE COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 129: EUROPE BREAST CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 130: EUROPE BREAST CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 131: EUROPE COLORECTAL CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 132: EUROPE COLORECTAL CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 133: EUROPE LUNG CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 134: EUROPE LUNG CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 135: EUROPE BLOOD CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 136: EUROPE BLOOD CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 137: EUROPE OTHER CANCER TYPE COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 138: EUROPE OTHER CANCER TYPE COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 139: EUROPE COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 140: EUROPE COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 141: GERMANY COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 142: GERMANY COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 143: GERMANY COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 144: GERMANY COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 145: GERMANY COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 146: GERMANY COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 147: GERMANY COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 148: GERMANY COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 149: UK COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 150: UK COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 151: UK COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 152: UK COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 153: UK COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 154: UK COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 155: UK COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 156: UK COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 157: FRANCE COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 158: FRANCE COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 159: FRANCE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 160: FRANCE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 161: FRANCE COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 162: FRANCE COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 163: FRANCE COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 164: FRANCE COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 165: RUSSIA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 166: RUSSIA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 167: RUSSIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 168: RUSSIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 169: RUSSIA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 170: RUSSIA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 171: RUSSIA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 172: RUSSIA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 173: SPAIN COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 174: SPAIN COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 175: SPAIN COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 176: SPAIN COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 177: SPAIN COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 178: SPAIN COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 179: SPAIN COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 180: SPAIN COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 181: ITALY COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 182: ITALY COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 183: ITALY COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 184: ITALY COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 185: ITALY COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 186: ITALY COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 187: ITALY COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 188: ITALY COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 189: REST OF EUROPE COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 190: REST OF EUROPE COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 191: REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 192: REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 193: REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 194: REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 195: REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 196: REST OF EUROPE COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 197: ASIA PACIFIC COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 198: ASIA PACIFIC COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 199: ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 200: ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 201: ASIA PACIFIC IMMUNOHISTOCHEMISTRY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 202: ASIA PACIFIC IMMUNOHISTOCHEMISTRY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 203: ASIA PACIFIC POLYMERASE CHAIN REACTION (PCR) MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 204: ASIA PACIFIC POLYMERASE CHAIN REACTION (PCR) MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 205: ASIA PACIFIC NEXT GENERATION SEQUENCING (NGS) MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 206: ASIA PACIFIC NEXT GENERATION SEQUENCING (NGS) MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 207: ASIA PACIFIC IN SITU HYBRIDIZATION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 208: ASIA PACIFIC IN SITU HYBRIDIZATION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 209: ASIA PACIFIC OTHER TECHNOLOGY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 210: ASIA PACIFIC OTHER TECHNOLOGY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 211: ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 212: ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 213: ASIA PACIFIC ONCOLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 214: ASIA PACIFIC ONCOLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 215: ASIA PACIFIC NEUROLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 216: ASIA PACIFIC NEUROLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 217: ASIA PACIFIC OTHER INDICATIONS COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 218: ASIA PACIFIC OTHER INDICATIONS COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 219: ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 220: ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 221: ASIA PACIFIC BREAST CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 222: ASIA PACIFIC BREAST CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 223: ASIA PACIFIC COLORECTAL CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 224: ASIA PACIFIC COLORECTAL CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 225: ASIA PACIFIC LUNG CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 226: ASIA PACIFIC LUNG CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 227: ASIA PACIFIC BLOOD CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 228: ASIA PACIFIC BLOOD CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 229: ASIA PACIFIC OTHER CANCER TYPE COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 230: ASIA PACIFIC OTHER CANCER TYPE COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 231: ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 232: ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 233: CHINA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 234: CHINA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 235: CHINA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 236: CHINA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 237: CHINA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 238: CHINA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 239: CHINA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 240: CHINA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 241: JAPAN COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 242: JAPAN COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 243: JAPAN COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 244: JAPAN COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 245: JAPAN COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 246: JAPAN COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 247: JAPAN COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 248: JAPAN COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 249: INDIA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 250: INDIA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 251: INDIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 252: INDIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 253: INDIA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 254: INDIA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 255: INDIA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 256: INDIA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 257: AUSTRALIA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 258: AUSTRALIA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 259: AUSTRALIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 260: AUSTRALIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 261: AUSTRALIA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 262: AUSTRALIA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 263: AUSTRALIA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 264: AUSTRALIA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 265: SOUTH KOREA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 266: SOUTH KOREA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 267: SOUTH KOREA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 268: SOUTH KOREA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 269: SOUTH KOREA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 270: SOUTH KOREA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 271: SOUTH KOREA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 272: SOUTH KOREA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 273: SINGAPORE COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 274: SINGAPORE COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 275: SINGAPORE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 276: SINGAPORE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 277: SINGAPORE COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 278: SINGAPORE COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 279: SINGAPORE COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 280: SINGAPORE COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 281: REST OF ASIA PACIFIC COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 282: REST OF ASIA PACIFIC COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 283: REST OF ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 284: REST OF ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 285: REST OF ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 286: REST OF ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 287: REST OF ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 288: REST OF ASIA PACIFIC COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 289: LAMEA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 290: LAMEA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 291: LAMEA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 292: LAMEA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 293: LAMEA IMMUNOHISTOCHEMISTRY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 294: LAMEA IMMUNOHISTOCHEMISTRY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 295: LAMEA POLYMERASE CHAIN REACTION (PCR) MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 296: LAMEA POLYMERASE CHAIN REACTION (PCR) MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 297: LAMEA NEXT GENERATION SEQUENCING (NGS) MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 298: LAMEA NEXT GENERATION SEQUENCING (NGS) MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 299: LAMEA IN SITU HYBRIDIZATION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 300: LAMEA IN SITU HYBRIDIZATION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 301: LAMEA OTHER TECHNOLOGY MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 302: LAMEA OTHER TECHNOLOGY MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 303: LAMEA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 304: LAMEA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 305: LAMEA ONCOLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 306: LAMEA ONCOLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 307: LAMEA NEUROLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 308: LAMEA NEUROLOGY COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 309: LAMEA OTHER INDICATIONS COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 310: LAMEA OTHER INDICATIONS COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 311: LAMEA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 312: LAMEA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 313: LAMEA BREAST CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 314: LAMEA BREAST CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 315: LAMEA COLORECTAL CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 316: LAMEA COLORECTAL CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 317: LAMEA LUNG CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 318: LAMEA LUNG CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 319: LAMEA BLOOD CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 320: LAMEA BLOOD CANCER COMPANION DIAGNOSTICS BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 321: LAMEA OTHER CANCER TYPE COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 322: LAMEA OTHER CANCER TYPE COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 323: LAMEA COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
  • TABLE 324: LAMEA COMPANION DIAGNOSTICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
  • TABLE 325: BRAZIL COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 326: BRAZIL COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 327: BRAZIL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 328: BRAZIL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 329: BRAZIL COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 330: BRAZIL COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 331: BRAZIL COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 332: BRAZIL COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 333: ARGENTINA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 334: ARGENTINA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 335: ARGENTINA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 336: ARGENTINA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 337: ARGENTINA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 338: ARGENTINA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 339: ARGENTINA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 340: ARGENTINA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 341: UAE COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 342: UAE COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 343: UAE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 344: UAE COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 345: UAE COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 346: UAE COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 347: UAE COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 348: UAE COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 349: SAUDI ARABIA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 350: SAUDI ARABIA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 351: SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 352: SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 353: SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 354: SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 355: SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 356: SAUDI ARABIA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 357: SOUTH AFRICA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 358: SOUTH AFRICA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 359: SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 360: SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 361: SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 362: SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 363: SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 364: SOUTH AFRICA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 365: NIGERIA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 366: NIGERIA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 367: NIGERIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 368: NIGERIA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 369: NIGERIA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 370: NIGERIA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 371: NIGERIA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 372: NIGERIA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 373: REST OF LAMEA COMPANION DIAGNOSTICS MARKET, 2015 - 2018, USD MILLION
  • TABLE 374: REST OF LAMEA COMPANION DIAGNOSTICS MARKET, 2019 - 2025, USD MILLION
  • TABLE 375: REST OF LAMEA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION
  • TABLE 376: REST OF LAMEA COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION
  • TABLE 377: REST OF LAMEA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2015 - 2018, USD MILLION
  • TABLE 378: REST OF LAMEA COMPANION DIAGNOSTICS MARKET BY INDICATION, 2019 - 2025, USD MILLION
  • TABLE 379: REST OF LAMEA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2015 - 2018, USD MILLION
  • TABLE 380: REST OF LAMEA COMPANION DIAGNOSTICS MARKET BY CANCER TYPE, 2019 - 2025, USD MILLION
  • TABLE 381: KEY INFORMATION - AGILENT TECHNOLOGIES, INC.
  • TABLE 382: KEY INFORMATION - ALMAC GROUP
  • TABLE 383: KEY INFORMATION - ARUP LABORATORIES, INC.
  • TABLE 384: KEY INFORMATION - ABBOTT LABORATORIES
  • TABLE 385: KEY INFORMATION - DANAHER CORPORATION
  • TABLE 386: KEY INFORMATION - THERMO FISHER SCIENTIFIC, INC.
  • TABLE 387: KEY INFORMATION - HOLOGIC, INC.
  • TABLE 388: KEY INFORMATION - NOVARTIS AG
  • TABLE 389: KEY INFORMATION - ILLUMINA, INC.
  • TABLE 390: KEY INFORMATION - QIAGEN N.V.

LIST OF FIGURES

  • FIG 1: METHODOLOGY FOR THE RESEARCH
目次

The Global Companion Diagnostics Market size is expected to reach $6.5 billion by 2025, rising at a market growth of 19.9% CAGR during the forecast period.

A companion diagnostics test is done to understand which patient can gain benefits from a specific drug or decide upon the kind of dosage that should be prescribed. All of this, on the basis of a patient's clinical diagnosis, which offers required evidence for the successful and harmless utilization of an equivalent biological or drug product to treat the medical issue. These can also be referred to as medical instruments that help doctors in electing which dosage or treatment is sufficient for patients and suits to their necessity.

The growth of research and development activities in the genetic sciences and biomarkers leads to new drug development mechanisms, dominated by companion diagnostics in the personalized medicine phase. Moreover, the development and usage of companion diagnostics have considerably improved the knowledge of the molecular causes of illnesses, the identification of many biomarkers and the development of targeted treatment.

Based on Technology, the market is segmented into Immunohistochemistry, Polymerase chain reaction (PCR), Next generation sequencing (NGS), In Situ Hybridization, and Other Technology. Based on Indication, the market is segmented into Oncology, Neurology and Other Indications. Further based on Cancer Type, the Oncology market is segmented into Breast Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer and Other Cancer Type. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Agilent Technologies, Inc., Almac Group, ARUP Laboratories, Inc., Abbott Laboratories (Abbott Laboratories Molecular, Inc.), Danaher Corporation, Thermo Fisher Scientific, Inc., Hologic, Inc., Novartis AG, Illumina, Inc., Qiagen N.V.

Scope of the Study

Market Segmentation:

By Technology

  • Immunohistochemistry
  • Polymerase chain reaction (PCR)
  • Next generation sequencing (NGS)
  • In Situ Hybridization and
  • Other Technology

By Indication

  • Oncology
  • Neurology and
  • Other Indications

By Cancer Type

  • Breast Cancer
  • Colorectal Cancer
  • Lung Cancer
  • Blood Cancer and
  • Other Cancer Type

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Australia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled:

  • Agilent Technologies, Inc.
  • Almac Group
  • ARUP Laboratories, Inc.
  • Abbott Laboratories (Abbott Laboratories Molecular, Inc.)
  • Danaher Corporation
  • Thermo Fisher Scientific, Inc.
  • Hologic, Inc.
  • Novartis AG
  • Illumina, Inc.
  • Qiagen N.V.

Unique Offerings from KBV Research:

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Companion Diagnostics Market, by Technology
    • 1.4.2 Global Companion Diagnostics Market, by Indication
    • 1.4.3 Global Companion Diagnostics Market, by Cancer Type
    • 1.4.4 Global Companion Diagnostics Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
    • 2.1.2 Executive Summary
    • 2.1.3 Market Composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Global Companion Diagnostics Market by Technology

  • 3.1 Global Immunohistochemistry Market by Region
  • 3.2 Global Polymerase chain reaction (PCR) Market by Region
  • 3.3 Global Next generation sequencing (NGS) Market by Region
  • 3.4 Global In Situ Hybridization Market by Region
  • 3.5 Global Other Technology Market by Region

Chapter 4. Global Companion Diagnostics Market by Indication

  • 4.1 Global Oncology Companion Diagnostics Market by Region
  • 4.2 Global Companion Diagnostics Market by Cancer Type
    • 4.2.1 Global Breast Cancer Companion Diagnostics by Region
    • 4.2.2 Global Colorectal Cancer Companion Diagnostics by Region
    • 4.2.3 Global Lung Cancer Companion Diagnostics by Region
    • 4.2.4 Global Blood Cancer Companion Diagnostics by Region
    • 4.2.5 Global Other Cancer Type Companion Diagnostics Market by Region
  • 4.3 Global Neurology Companion Diagnostics Market by Region
  • 4.4 Global Other Indications Companion Diagnostics Market by Region

Chapter 5. Global Companion Diagnostics Market by Region

  • 5.1 North America Companion Diagnostics Market
    • 5.1.1 North America Companion Diagnostics Market by Technology
      • 5.1.1.1 North America Immunohistochemistry Market by Country
      • 5.1.1.2 North America Polymerase chain reaction (PCR) Market by Country
      • 5.1.1.3 North America Next generation sequencing (NGS) Market by Country
      • 5.1.1.4 North America In Situ Hybridization Market by Country
      • 5.1.1.5 North America Other Technology Market by Country
    • 5.1.2 North America Companion Diagnostics Market by Indication
      • 5.1.2.1 North America Oncology Companion Diagnostics Market by Country
      • 5.1.2.2 North America Neurology Companion Diagnostics Market by Country
      • 5.1.2.3 North America Other Indications Companion Diagnostics Market by Country
    • 5.1.3 North America Companion Diagnostics Market by Cancer Type
      • 5.1.3.1 North America Breast Cancer Companion Diagnostics by Country
      • 5.1.3.2 North America Colorectal Cancer Companion Diagnostics by Country
      • 5.1.3.3 North America Lung Cancer Companion Diagnostics by Country
      • 5.1.3.4 North America Blood Cancer Companion Diagnostics by Country
      • 5.1.3.5 North America Other Cancer Type Companion Diagnostics Market by Country
    • 5.1.4 North America Companion Diagnostics Market by Country
      • 5.1.4.1 USA Companion Diagnostics Market
        • 5.1.4.1.1 USA Companion Diagnostics Market by Technology
        • 5.1.4.1.2 USA Companion Diagnostics Market by Indication
      • 5.1.4.2 Canada Companion Diagnostics Market
        • 5.1.4.2.1 Canada Companion Diagnostics Market by Technology
        • 5.1.4.2.2 Canada Companion Diagnostics Market by Indication
      • 5.1.4.3 Mexico Companion Diagnostics Market
        • 5.1.4.3.1 Mexico Companion Diagnostics Market by Technology
        • 5.1.4.3.2 Mexico Companion Diagnostics Market by Indication
      • 5.1.4.4 Rest of North America Companion Diagnostics Market
        • 5.1.4.4.1 Rest of North America Companion Diagnostics Market by Technology
        • 5.1.4.4.2 Rest of North America Companion Diagnostics Market by Indication
  • 5.2 Europe Companion Diagnostics Market
    • 5.2.1 Europe Companion Diagnostics Market by Technology
      • 5.2.1.1 Europe Immunohistochemistry Market by Country
      • 5.2.1.2 Europe Polymerase chain reaction (PCR) Market by Country
      • 5.2.1.3 Europe Next generation sequencing (NGS) Market by Country
      • 5.2.1.4 Europe In Situ Hybridization Market by Country
      • 5.2.1.5 Europe Other Technology Market by Country
    • 5.2.2 Europe Companion Diagnostics Market by Indication
      • 5.2.2.1 Europe Oncology Companion Diagnostics Market by Country
      • 5.2.2.2 Europe Neurology Companion Diagnostics Market by Country
      • 5.2.2.3 Europe Other Indications Companion Diagnostics Market by Country
      • 5.2.2.4 Europe Companion Diagnostics Market by Cancer Type
        • 5.2.2.4.1 Europe Breast Cancer Companion Diagnostics by Country
        • 5.2.2.4.2 Europe Colorectal Cancer Companion Diagnostics by Country
        • 5.2.2.4.3 Europe Lung Cancer Companion Diagnostics by Country
        • 5.2.2.4.4 Europe Blood Cancer Companion Diagnostics by Country
        • 5.2.2.4.5 Europe Other Cancer Type Companion Diagnostics Market by Country
    • 5.2.3 Europe Companion Diagnostics Market by Country
      • 5.2.3.1 Germany Companion Diagnostics Market
        • 5.2.3.1.1 Germany Companion Diagnostics Market by Technology
        • 5.2.3.1.2 Germany Companion Diagnostics Market by Indication
      • 5.2.3.2 UK Companion Diagnostics Market
        • 5.2.3.2.1 UK Companion Diagnostics Market by Technology
        • 5.2.3.2.2 UK Companion Diagnostics Market by Indication
      • 5.2.3.3 France Companion Diagnostics Market
        • 5.2.3.3.1 France Companion Diagnostics Market by Technology
        • 5.2.3.3.2 France Companion Diagnostics Market by Indication
      • 5.2.3.4 Russia Companion Diagnostics Market
        • 5.2.3.4.1 Russia Companion Diagnostics Market by Technology
        • 5.2.3.4.2 Russia Companion Diagnostics Market by Indication
      • 5.2.3.5 Spain Companion Diagnostics Market
        • 5.2.3.5.1 Spain Companion Diagnostics Market by Technology
        • 5.2.3.5.2 Spain Companion Diagnostics Market by Indication
      • 5.2.3.6 Italy Companion Diagnostics Market
        • 5.2.3.6.1 Italy Companion Diagnostics Market by Technology
        • 5.2.3.6.2 Italy Companion Diagnostics Market by Indication
      • 5.2.3.7 Rest of Europe Companion Diagnostics Market
        • 5.2.3.7.1 Rest of Europe Companion Diagnostics Market by Technology
        • 5.2.3.7.2 Rest of Europe Companion Diagnostics Market by Indication
  • 5.3 Asia Pacific Companion Diagnostics Market
    • 5.3.1 Asia Pacific Companion Diagnostics Market by Technology
      • 5.3.1.1 Asia Pacific Immunohistochemistry Market by Country
      • 5.3.1.2 Asia Pacific Polymerase chain reaction (PCR) Market by Country
      • 5.3.1.3 Asia Pacific Next generation sequencing (NGS) Market by Country
      • 5.3.1.4 Asia Pacific In Situ Hybridization Market by Country
      • 5.3.1.5 Asia Pacific Other Technology Market by Country
    • 5.3.2 Asia Pacific Companion Diagnostics Market by Indication
      • 5.3.2.1 Asia Pacific Oncology Companion Diagnostics Market by Country
      • 5.3.2.2 Asia Pacific Neurology Companion Diagnostics Market by Country
      • 5.3.2.3 Asia Pacific Other Indications Companion Diagnostics Market by Country
      • 5.3.2.4 Asia Pacific Companion Diagnostics Market by Cancer Type
        • 5.3.2.4.1 Asia Pacific Breast Cancer Companion Diagnostics by Country
        • 5.3.2.4.2 Asia Pacific Colorectal Cancer Companion Diagnostics by Country
        • 5.3.2.4.3 Asia Pacific Lung Cancer Companion Diagnostics by Country
        • 5.3.2.4.4 Asia Pacific Blood Cancer Companion Diagnostics by Country
        • 5.3.2.4.5 Asia Pacific Other Cancer Type Companion Diagnostics Market by Country
    • 5.3.3 Asia Pacific Companion Diagnostics Market by Country
      • 5.3.3.1 China Companion Diagnostics Market
        • 5.3.3.1.1 China Companion Diagnostics Market by Technology
        • 5.3.3.1.2 China Companion Diagnostics Market by Indication
      • 5.3.3.2 Japan Companion Diagnostics Market
        • 5.3.3.2.1 Japan Companion Diagnostics Market by Technology
        • 5.3.3.2.2 Japan Companion Diagnostics Market by Indication
      • 5.3.3.3 India Companion Diagnostics Market
        • 5.3.3.3.1 India Companion Diagnostics Market by Technology
        • 5.3.3.3.2 India Companion Diagnostics Market by Indication
      • 5.3.3.4 Australia Companion Diagnostics Market
        • 5.3.3.4.1 Australia Companion Diagnostics Market by Technology
        • 5.3.3.4.2 Australia Companion Diagnostics Market by Indication
      • 5.3.3.5 South Korea Companion Diagnostics Market
        • 5.3.3.5.1 South Korea Companion Diagnostics Market by Technology
        • 5.3.3.5.2 South Korea Companion Diagnostics Market by Indication
      • 5.3.3.6 Singapore Companion Diagnostics Market
        • 5.3.3.6.1 Singapore Companion Diagnostics Market by Technology
        • 5.3.3.6.2 Singapore Companion Diagnostics Market by Indication
      • 5.3.3.7 Rest of Asia Pacific Companion Diagnostics Market
        • 5.3.3.7.1 Rest of Asia Pacific Companion Diagnostics Market by Technology
        • 5.3.3.7.2 Rest of Asia Pacific Companion Diagnostics Market by Indication
  • 5.4 LAMEA Companion Diagnostics Market
    • 5.4.1 LAMEA Companion Diagnostics Market by Technology
      • 5.4.1.1 LAMEA Immunohistochemistry Market by Country
      • 5.4.1.2 LAMEA Polymerase chain reaction (PCR) Market by Country
      • 5.4.1.3 LAMEA Next generation sequencing (NGS) Market by Country
      • 5.4.1.4 LAMEA In Situ Hybridization Market by Country
      • 5.4.1.5 LAMEA Other Technology Market by Country
    • 5.4.2 LAMEA Companion Diagnostics Market by Indication
      • 5.4.2.1 LAMEA Oncology Companion Diagnostics Market by Country
      • 5.4.2.2 LAMEA Neurology Companion Diagnostics Market by Country
      • 5.4.2.3 LAMEA Other Indications Companion Diagnostics Market by Country
      • 5.4.2.4 LAMEA Companion Diagnostics Market by Cancer Type
        • 5.4.2.4.1 LAMEA Breast Cancer Companion Diagnostics by Country
        • 5.4.2.4.2 LAMEA Colorectal Cancer Companion Diagnostics by Country
        • 5.4.2.4.3 LAMEA Lung Cancer Companion Diagnostics by Country
        • 5.4.2.4.4 LAMEA Blood Cancer Companion Diagnostics by Country
        • 5.4.2.4.5 LAMEA Other Cancer Type Companion Diagnostics Market by Country
    • 5.4.3 LAMEA Companion Diagnostics Market by Country
      • 5.4.3.1 Brazil Companion Diagnostics Market
        • 5.4.3.1.1 Brazil Companion Diagnostics Market by Technology
        • 5.4.3.1.2 Brazil Companion Diagnostics Market by Indication
      • 5.4.3.2 Argentina Companion Diagnostics Market
        • 5.4.3.2.1 Argentina Companion Diagnostics Market by Technology
        • 5.4.3.2.2 Argentina Companion Diagnostics Market by Indication
      • 5.4.3.3 UAE Companion Diagnostics Market
        • 5.4.3.3.1 UAE Companion Diagnostics Market by Technology
        • 5.4.3.3.2 UAE Companion Diagnostics Market by Indication
      • 5.4.3.4 Saudi Arabia Companion Diagnostics Market
        • 5.4.3.4.1 Saudi Arabia Companion Diagnostics Market by Technology
        • 5.4.3.4.2 Saudi Arabia Companion Diagnostics Market by Indication
      • 5.4.3.5 South Africa Companion Diagnostics Market
        • 5.4.3.5.1 South Africa Companion Diagnostics Market by Technology
        • 5.4.3.5.2 South Africa Companion Diagnostics Market by Indication
      • 5.4.3.6 Nigeria Companion Diagnostics Market
        • 5.4.3.6.1 Nigeria Companion Diagnostics Market by Technology
        • 5.4.3.6.2 Nigeria Companion Diagnostics Market by Indication
      • 5.4.3.7 Rest of LAMEA Companion Diagnostics Market
        • 5.4.3.7.1 Rest of LAMEA Companion Diagnostics Market by Technology
        • 5.4.3.7.2 Rest of LAMEA Companion Diagnostics Market by Indication

Chapter 6. Company Profiles

  • 6.1 Agilent Technologies, Inc.
    • 6.1.1 Company Overview
    • 6.1.2 Financial Analysis
    • 6.1.3 Segmental and Regional Analysis
    • 6.1.4 Research & Development Expense
    • 6.1.5 Recent strategies and developments:
      • 6.1.5.1 Product launches:
      • 6.1.5.2 Expansions:
  • 6.2 Almac Group
    • 6.2.1 Company Overview
    • 6.2.1 Recent strategies and developments:
      • 6.2.1.1 Collaborations, partnerships and agreements:
  • 6.3 ARUP Laboratories, Inc.
    • 6.3.1 Company Overview
  • 6.4 Abbott Laboratories (Abbott Laboratories Molecular, Inc.)
    • 6.4.1 Company Overview
    • 6.4.2 Financial Analysis
    • 6.4.3 Segmental and Regional Analysis
    • 6.4.4 Research & Development Expense
  • 6.5 Danaher Corporation
    • 6.5.1 Company Overview
    • 6.5.2 Financial Analysis
    • 6.5.3 Segmental and Regional Analysis
    • 6.5.4 Research & Development Expense
    • 6.5.5 Recent strategies and developments:
      • 6.5.5.1 Acquisition and mergers:
  • 6.6 Thermo Fischer Scientific, Inc.
    • 6.6.1 Company Overview
    • 6.6.2 Financial Analysis
    • 6.6.3 Segmental and Regional Analysis
    • 6.6.4 Research & Development Expense
    • 6.6.5 Recent strategies and developments:
      • 6.6.5.1 Collaborations, partnerships and agreements:
      • 6.6.5.2 Expansions:
  • 6.7 Hologic, Inc.
    • 6.7.1 Company Overview
    • 6.7.2 Financial Analysis
    • 6.7.3 Segmental and Regional Analysis
    • 6.7.4 Research & Development Expense
    • 6.7.5 Recent strategies and developments:
      • 6.7.5.1 Product launches:
      • 6.7.5.2 Acquisition and mergers:
  • 6.8 Novartis AG
    • 6.8.1 Company Overview
    • 6.8.2 Financial Analysis
    • 6.8.3 Segmental and Regional Analysis
    • 6.8.4 Research & Development Expense
    • 6.8.5 Recent strategies and developments:
      • 6.8.5.1 Collaborations, partnerships and agreements:
  • 6.9 Illumina, Inc.
    • 6.9.1 Company Overview
    • 6.9.2 Financial Analysis
    • 6.9.3 Regional Analysis
    • 6.9.4 Research & Development Expense
    • 6.9.5 Recent strategies and developments:
      • 6.9.5.1 Product launches:
      • 6.9.5.2 Acquisition and mergers:
      • 6.9.5.3 Collaborations, partnerships and agreements:
  • 6.1 Qiagen N.V.
    • 6.10.1 Company Overview
    • 6.10.2 Financial Analysis
    • 6.10.3 Regional Analysis
    • 6.10.4 Research & Development Expense
    • 6.10.5 Recent strategies and developments:
      • 6.10.5.1 Product launches:
      • 6.10.5.2 Collaborations, partnerships and agreements:
Back to Top